Printer Friendly

Vitamin B-6, Independent of Homocysteine, Is a Significant Factor in Relation to Inflammatory Responses for Chronic Kidney Disease and Hemodialysis Patients.

1. Introduction

Patients with chronic kidney disease (CKD) or receiving hemodialysis treatment are under persistent low-grade inflammatory status [1-6] and have been suggested to experience poorer clinical conditions and higher mortality when they had persistent elevated levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8), or tumor necrosis factor-[alpha] (TNF-[alpha]) [7-9]. Manyfactors maybe associated with inflammation for CKD and hemodialysis patients; however, its causes have not been fully elucidated.

Low vitamin B-6 status [10-12] and hyperhomocysteinemia [13-15] commonly exist in patients with CKD or those receiving hemodialysis treatment, and these two factors could be implicated in inflammatory responses. Plasma pyridoxal 5 -phosphate (PLP, an active form of vitamin B-6) possibly acts as a coenzyme for the production of cytokines and other polypeptide mediators during the inflammatory responses [16]. The relationship between low vitamin B-6 levels and levels of inflammatory markers has been observed in patients with inflammatory diseases [17-20] and even independently of plasma homocysteine in the population-based Framingham Heart cohort study [16]. However, no association between plasma PLP and cytokine levels [i.e., IL-6, interleukin-10 (IL-10) and transforming growth factor-[beta]] was found in kidney transplant recipients [21, 22]. In addition to the relationship between vitamin B-6 and inflammation, a high homocysteine concentration was also significantly correlated with inflammatory markers (i.e., CRP, IL-6, IL-8, and TNF-[alpha]) among the elderly and patients with cardiovascular disease [23-26]. Homocysteine is oxidized to form a disulfide bond with another homocysteine or protein when it is released from the cell into the blood circulation via a superoxide free radical which is released at the same time [24]. This can then give rise to oxidative and nitrosative stress and initiate inflammation via the regulation of NF-[kappa]B transcription [27, 28]. Although homocysteine can be used as an inflammatory marker to indicate the presence of inflammation, increased homocysteine concentration and elevated inflammatory markers were not always associated with each other [24]. Since the discrepancy between vitamin B-6 or homocysteine and inflammation still exists, the roles vitamin B-6 and homocysteine status play in the inflammatory responses need to be further confirmed.

Plasma PLP is an essential coenzyme of transsulfuration in homocysteine metabolism, so a low or deficient PLP may thus cause the accumulation of homocysteine. If CKD patients or hemodialysis patients were potentially under persistent low-grade inflammation and had low vitamin B6 levels and a high homocysteine status, questions would be raised to whether there were associations among vitamin B6, homocysteine concentrations, and inflammatory markers and whether vitamin B-6 and homocysteine were dependent on or independent of each other when associated with inflammatory markers. Therefore, the purpose of this study was to investigate the dependent or independent association of plasma PLP and homocysteine with inflammatory markers in both CKD and hemodialysis patients.

2. Subjects and Methods

2.1. Study Design and Sample Size Calculation. This was a cross-sectional study. A previous study indicated that plasma PLP was significantly associated with CRP (partial r = -0.25, p < 0.05) [20]. Thus we needed a sample size of 124 subjects based on a power of 80% and a 2-sided test with [alpha] of 0.05 to detect a significant correlation coefficient of 0.25 between plasma PLP and CRP levels.

2.2. Subjects. Patients fell within the ages of 20 to 85 years and either were with stage 2-5 CKD [estimated glomerular filtration (eGFR) [less than or equal to] 89 mL/min/1.73 [m.sup.2]] or were receiving hemodialysis treatment with high-flux polysulfone membrane dialyzers (FX 80[R] or FX 100[R]) operated by Fresenius 4008S dialysis systems (Fresenius Medical Care AG & Co., Bad Homburg, Germany) for 4 hours three times per week. They were recruited from the outpatient clinic and the hemodialysis center of the Division of Nephrology of Taichung Veterans General Hospital, Taiwan. Patients' diagnoses and CKD staging were confirmed by an experienced nephrologist. Exclusion criteria included patients who were clinically unstable, pregnant, lactating, or having a history of liver disease, chronic inflammatory disease, cancer, or alcoholism. This study was approved by the Institutional Review Board of Taichung Veterans General Hospital (IRB TCVGH numbers SF13223 and SF15019A). Participants provided their informed consent prior to enter the study.

2.3. Data Collection and Biochemical Measurements. Subjects' age, gender, smoking, and drinking habits, along with their nutritional supplements were recorded. CKD patients' height, weight, waist circumference, and systolic and diastolic blood pressure (SBP and DBP) were measured on an appointed day while patients receiving hemodialysis treatment were measured on an appointed day at a prehemodialysis session. Body mass was then calculated.

Blood samples taken after a period of fasting were drawn and collected in vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ, USA) containing ethylenediaminete-traacetic acid as the anticoagulant or with no anticoagulant on an appointed day for CKD patients and on an appointed day (the second dialysis session of the week) at a prehemodialysis session for hemodialysis patients. Serum or plasma was separated within 30 minutes after blood was collected and immediately measured or then frozen (-80[degrees]C) until analysis. Serum albumin, glucose, total cholesterol, creatinine, and blood urea nitrogen were measured using an automated biochemical analyzer. Automated high-sensitivity CRP measurement concentration was performed using particle-enhanced immunonephelometry with an image analyzer. Plasma PLP, pyridoxal (PL), and homocysteine were quantified by high performance liquid chromatography using fluorescence detection following the methods of Talwar et al. [29] and Araki and Sako [30]. Vitamin B-6 deficiency was defined as a plasma PLP level < 20 nmol/L [31]. Hyperhomocysteinemia was defined as a plasma homocysteine concentration [greater than or equal to] 14 [micro]mol/L [32]. Homocysteine and vitamin B-6 measurements were carried out under yellow light to prevent photodestruction. Different plasma cytokine levels [i.e., interleukin-1[beta] (IL-1[beta]), interleukin-4 (IL-4), IL-6, IL-8, IL-10, and TNF-[alpha]] were analyzed by using a magnetic bead-based multiplex immunoassay system (Bio-Plex) (BIO-RAD Laboratories, UK) following the manufacturer's instructions. All analyses were performed in duplicate.

2.4. Statistical Analyses. All data analyses were performed by using the SAS statistical software package (version 9.3; Statistical Analysis System Institute Inc., Cary, NC, USA). A Shapiro-Wilk test was performed to test the normal distribution. Differences in patients' anthropometric measurements and biochemical values were compared for significant differences amongst the groups and analyzed by a one-way analysis of variance or Kruskal-Wallis one-way analysis of variance on ranks. For categorical response variables, differences amongst the groups were assessed by the Chi-square test. A partial Spearman correlation coefficient (rs) was used to analyze the correlations of plasma PLP, PL, and homocysteine with inflammatory markers after adjusting for the potential confounders. Results were considered statistically significant at p < 0.05. Values presented in the text are means [+ or -] standard error (SE).

3. Results

Of sixty-eight total patients, 13 had stage 2 (eGFR, 60-89 mL/ min/1.73 [m.sup.2]), 21 had stage 3 (eGFR, 30-59 mL/min/1.73[m.sup.2]), 21 had stage 4 (eGFR, 15-29 mL/min/1.73[m.sup.2]), and 13 had stage 5 (eGFR, <15 mL/min/1.73 [m.sup.2]) CKD. The main etiologies of CKD were diabetic nephrology, IgA nephrology, gouty nephrology, nephrotic syndrome, or tubulointerstitial nephritis. An additional 68 patients receiving hemodialysis treatments were also recruited for this study. Patients had been dialyzed for 7.63 [+ or -] 7.82 year. There were similar results between stages 2 and 3, and stages 4 and 5 (data not shown). We then pooled stage 2 and 3 CKD patients (n = 34) into an early CKD stage group (eGFR, 33.15-88.04 mL/min/1.73 [m.sup.2]; median eGFR, 53.63 mL/min/1.73 [m.sup.2]) and along with pooling stage 4 and 5 patients (n = 34) into an advanced CKD stage group (eGFR, 6.97-29.13 mL/min/1.73 m; median eGFR, 17.88 mL/min/1.73 [m.sup.2]) based on the clinical description of CKD stages in order to increase the studies statistical strength.

Patients receiving hemodialysis treatment were the oldest in age and had a lowest eGFR level and the highest SBP, serum creatinine, and BUN levels, while patients in the early CKD stage were the youngest and had the highest eGFR level and the lowest SBP, serum creatinine, and BUN levels amongst the 3 groups (Table 1). There were no significant differences in BMI, DBP, and serum glucose levels among groups (Table 1). Only one hemodialysis patient had a BMI < 18.5 indicating underweight. More than one-third of patients receiving hemodialysis treatments were taking B-vitamin supplements, while no early CKD stage patients had taken B-vitamin (folate, vitamin B-6, and vitamin B-12) supplements (Table 1).

Table 2 shows vitamin B-6 and homocysteine concentrations, along with levels of inflammatory markers in the 3 groups. Early CKD stage patients displayed significantly lower plasma PLP and homocysteine concentrations than the patients who were receiving hemodialysis treatments. However, there was no significant difference in plasma PL concentration among the 3 groups. Only 10 patients had a vitamin B-6 deficiency (plasma PLP level < 20 nmol/L). There was a 91.2% prevalence of hyperhomocysteinemia (plasma homocysteine concentration [greater than or equal to] 14 [micro]mol/L) in our patients. Since B-vitamin supplement use may affect homocysteine concentration, we further compared the plasma homocysteine concentration between patients who were taking or not taking B-vitamin supplements within the advanced CKD stage and hemodialysis group. Patients who were taking Bvitamin supplements had a significantly lower plasma homocysteine concentration than patients who were not taking Bvitamin supplements (22.93 [+ or -] 3.08 vs. 29.36 [+ or -] 1.74[micro]mol/L) in the advanced CKD stage group. Hemodialysis patients who were taking B-vitamin supplements had only slightly, not significantly, lower plasma homocysteine concentration than patients who were not taking B-vitamin supplements (25.75 [+ or -] 1.18 versus 28.34 [+ or -] 1.66 [micro]ol/L). There were no significant differences in IL-4, IL-6, and IL-8 levels among the 3 groups, while CRP, IL-1[beta], IL-10, and TNF-[alpha] levels remained significantly different among the 3 groups.

We excluded 39 patients who were taking B-vitamin supplementation in order to understand the association between vitamin B-6 status and inflammatory markers without the confounding of B-vitamin supplement use. The associations were similar between vitamin B-6 status and inflammatory markers with and without including patients who were taking B-vitamin supplementation (data not shown). We thus presented the results for all patients (n = 136), adjusting B-vitamin supplement use during partial Spearman correlation coefficient analyses. Plasma PLP significantly correlated with CRP levels, while plasma PL significantly correlated with IL-10 level and plasma PLP + PL significantly correlated with CRP and IL-1[beta] levels after adjusting for age, gender, BMI, SBP, serum albumin concentration, diabetes, CKD stage, B-vitamin supplement use, smoking, and drinking habits and finally additionally adjusting for plasma homocysteine concentration (Table 3). There was no association found between plasma PLP and homocysteine concentration, and plasma homocysteine concentration was not correlated with any inflammatory markers after adjusting for potential confounders (data not shown).

4. Discussion

To the best of our knowledge, the relationship between vitamin B-6 status, plasma homocysteine, and inflammatory markers has not been simultaneously or extensively investigated in CKD and hemodialysis patients. Cytokines are released from inflammatory cells and drive the inflammatory process. For example, IL-1[beta], has a strong proinflammatory role; IL-6 and TNF-[alpha] are active contributors to acute inflammatory responses. We thus assessed plasma PLP, PL, and homocysteine concentrations, as well as different cytokine markers in our CKD and hemodialysis patients.

In the vitamin B-6 metabolism, PLP is dephosphorylated by alkaline phosphatase to PL before entering the cell, where the PL is then reformed to PLP by pyridoxine kinase. Since the interconversion between PLP and PL is reversible and widely distributed, plasma PLP + PL can thus be considered as a single pool of vitamin B-6 [20]. We then combined plasma PLP and PL and observed that the plasma PLP + PL correlated with CRP and IL-1[beta]. In accord with the previous study [20], plasma PLP + PL as well as individual plasma PLP or plasma PL could indicate that vitamin B6 catabolism is increased during inflammation. We recommend that plasma PLP and PL be simultaneously assessed in CKD and hemodialysis patients.

CRP is produced in the liver and its level rises rapidly after an inflammatory stimulus. We excluded clinically unstable CKD and hemodialysis patients, and our patients were regularly checked up by the nephrologist and had the stable disease condition which may not cause too severe inflammatory responses; it might be the reason for our patients had substantially lower CRP levels when compared to the data of patients from the National Health and Nutrition Examination Survey III (NHANS III) [1] and other studies [9]. However, our advanced CKD stage and hemodialysis patients had higher CRP levels than early CKD stage patients. The association between low plasma PLP and high CRP levels not only was observed in patients with inflammatory diseases [17-20] but also was presented in patients with type 2 diabetic nephrology [33], along with patients with CKD and those undergoing hemodialysis in the present study. In contrast with Jankowska et al. [21], an indication of no relationship between plasma PLP or PL and inflammatory markers was due to the lack of vitamin B-6 deficiency in their kidney allograft recipients. Although 7.4% of our patients had plasma PLP < 20 nmol/L and 23.5% of our patients (particularly those in advanced CKD stage and those undergoing hemodialysis) were taking vitamin B-6 supplements which led to the mean plasma PLP level having an adequate status (>20 nmol/L) and levels in a large variation, significant associations between vitamin B-6 and CRP, IL-1[beta], and IL-10 existed in our CKD and hemodialysis patients. Even though patients who were taking B-vitamin supplements were excluded in order to reduce the variation of plasma PLP and PL, we still observed the significant associations between vitamin B-6 status and inflammatory markers in our patients. Paul et al. [34] revealed out that the negative association between plasma PLP and inflammatory responses was not truly linked to vitamin B-6 deficiency but was rather associated with a metabolic phenomenon inherent to inflammation. Zhang et al. [35] indicated that higher physiological concentrations of PLP and PL are needed to inhibit both Toll-like receptor-induced NF-[gamma]B activation and NLRP3-mediated caspase-1 activation to eradicate IL-1[beta] production in macrophages [35]. It seems that a higher vitamin B-6 status is required for CKD and hemodialysis patients to cope with their inflammatory responses. In addition, a higher need for vitamin B6 may not be mediated through homocysteine, since plasma homocysteine was additionally adjusted in the correlation analyses and there was no correlation seen between plasma PLP and homocysteine. Other mechanisms may also be involved in vitamin B-6 and inflammation. Vitamin B-6 could be stemming from the mobilization of plasma PLP to an inflammatory site for degradation of tryptophan via the kynurenine pathway, metabolism of immunomodulatory sphingolipids, and the proliferation of immune cells [16, 34, 36].

Circulating inflammatory markers, such as IL-6, IL-8, and TNF-[alpha], have been shown to be associated with the loss of renal function [4], while IL-6 and TNF-[alpha] have been considered as good inflammatory markers for risk stratification in CKD [3, 6, 7, 37]. Although both IL-6 and TNF-[alpha] stimulate CRP production, we only observed that vitamin B-6 status correlated with CRP but did not correlate with IL-4, IL-6, IL8, and TNF-[alpha]. IL-6 and TNF-[alpha] are proinflammatory mediators and systemically increase rapidly (~1.5-3 hours) while CRP levels increase slightly later (~6-8 hours) following tissue injury [8]; therefore a large interindividual variation for these inflammatory markers (IL-6 and TNF-[alpha]) may be a possible reason for there being no significant associations of vitamin B-6 with these inflammatory markers in the present study.

One of the major causes of hyperhomocysteinemia might be due to loss of renal function [15, 38, 39]. In concordance with previous studies [40-43], hyperhomocysteinemia was prevalent in our CKD and hemodialysis patients, and homocysteine levels were 2-fold higher in hemodialysis patients than those in early stage CKD in the present study. However, unlike previous studies [23-26, 41], hyperhomocysteinemia did not contribute to inflammatory responses in our CKD and hemodialysis patients. There was also no significant association shown between homocysteine and CRP in ischemic stroke patients [44] or homocysteine and IL-6 levels in the general population [45]. Although hyperhomocysteinemia has been implicated as an important risk factor of inflammatory responses [23-26, 41], cardiovascular disease, and mortality [42, 43] in CKD and hemodialysis patients, the beneficial effect of B-vitamin supplementation on lowering plasma homocysteine concentration in CKD and hemodialysis patients has not been confirmed [42, 43]. B-vitamin deficiency, increased oxidative stress, or other factors may be directly rather than indirectly (via elevated homocysteine levels) associated with acute or chronic inflammation; therefore, increased homocysteine concentrations and elevated inflammatory markers were not always associated with each other [24]. In the present study, vitamin B-6 status is independent of homocysteine, and being associated with inflammatory responses may support this hypothesis.

One limitation of this study was the use of a small number of stage 2-5 CKD patients as compared to the number of hemodialysis patients. The final recruitment number in the present study was larger than our sample size calculation; however, a greater number of patients may increase the statistical power to possibly reveal a more significant association between vitamin B-6 status and cytokine levels. Although we have excluded clinically unstable patients in the present study, cytokine levels in elderly adults have been reported to be varied day-to-day [46], while intraindividual variability of CKD and hemodialysis patients might be even greater than the variability in the general population. We did not measure the levels of other water soluble vitamins, such as folate and vitamin B-12, which might affect plasma homocysteine concentration and cytokine levels. Another limitation was that a cross-sectional design caused one time of blood test and therefore could not generally reflect long-term vitamin B-6, homocysteine, and inflammatory status. A longitudinal study seems necessary to better clarify the association of vitamin B6 status, homocysteine, and inflammatory markers in CKD and hemodialysis patients.

5. Conclusions

Taken together, vitamin B-6 status rather than homocysteine seemed to be a significant factor in relation to inflammatory responses for CKD and hemodialysis patients. Further study regarding the association between homocysteine and inflammatory responses is warranted and must therefore be further investigated. 10.1155/2017/7367831


This study is part of En-Ling Yeh's doctoral research.

Conflicts of Interest

All authors have no conflicts of interest.


This study was partially supported by Taichung Veterans General Hospital (TCVGH-1063604D) and Taichung Veterans General Hospital, Chiayi Branch (RVHCY105001), Taiwan.


[1] J. A. Eustace, B. Astor, P. M. Muntner, T. A. Ikizler, and J. Coresh, "Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease," Kidney International, vol. 65, no. 3, pp. 1031-1040, 2004.

[2] J. J. Carrero and P. Stenvinkel, "Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal," Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. S49-S55, 2009.

[3] J. J. Carrero and P. Stenvinkel, "Inflammation in end-stage renal disease-what have we learned in 10 years?" Seminars in Dialysis, vol. 23, no. 5, pp. 498-509, 2010.

[4] T. Miyamoto, J. J. Carrero, and P. Stenvinkel, "Inflammation as a risk factor and target for therapy in chronic kidney disease," Current Opinion in Nephrology and Hypertension, vol. 20, no. 6, pp. 662-668, 2011.

[5] J. Kotur-Stevuljevic, S. Simic-Ogrizovic, V. Dopsaj et al., "A hazardous link between malnutrition, inflammation and oxidative stress in renal patients," Clinical Biochemistry, vol. 45, no. 15, pp. 1202-1205, 2012.

[6] J. D. Imig and M. J. Ryan, "Immune and inflammatory role in renal disease," Comprehensive Physiology, vol. 3, no. 2, pp. 957976, 2013.

[7] D. V Barreto, F. C. Barreto, S. Liabeuf et al., "Plasma interleukin6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease," Kidney International, vol. 77, no. 6, pp. 550-556, 2010.

[8] C. L. Meuwese, P. Stenvinkel, F. W. Dekker, and J. J. Carrero, "Monitoring of inflammation in patients on dialysis: Forewarned is forearmed," Nature Reviews Nephrology, vol. 7, no. 3, pp. 166-176, 2011.

[9] C. L. Meuwese, S. Snaedal, N. Halbesma et al., "Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-[alpha] are similarly associated with survival in haemodialysis patients," Nephrology Dialysis Transplantation, vol. 26, no. 4, pp. 1313-1318, 2011.

[10] S. P. Coburn, R. D. Reynolds, J. D. Mahuren et al., "Elevated plasma 4-pyridoxic acid in renal insufficiency," The American Journal of Clinical Nutrition, vol. 75, pp. 57-64, 2002.

[11] M. Mydllk and K. Derzsiova, "Vitamin B6 and oxalic acid in clinical nephrology," Journal of Renal Nutrition, vol. 20, no. 5, pp. S95-S102, 2010.

[12] M. Corken and J. Porter, "Is vitamin B 6 deficiency an underrecognized risk in patients receiving haemodialysis? A systematic review: 2000-2010," Nephrology, vol. 16, no. 7, pp. 619-625, 2011.

[13] M. Busch, A. Gobert, S. Franke et al., "Vitamin B6 metabolism in chronic kidney disease-relation to transsulfuration, advanced glycation and cardiovascular disease.," Nephron. Clinical practice, vol. 114, no. 1, pp. c38-46, 2010.

[14] N. Nand, M. Sharma, and N. Mittal, "Prevalence of hyperhomocysteinaemia in chronic kidney disease and effect of supplementation of folic acid and vitamin B12 on cardiovascular mortality," Journal, Indian Academy of Clinical Medicine, vol. 14, no. 1, pp. 33-36, 2013.

[15] A. Levi, E. Cohen, M. Levi, E. Goldberg, M. Garty, and I. Krause, "Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease: a historical prospective study," European Journal of Internal Medicine, vol. 25, no. 10, pp. 951-955, 2014.

[16] S. Friso, P. F. Jacques, P. W. F. Wilson, I. H. Rosenberg, and J. Selhub, "Low circulating vitamin B6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels," Circulation, vol. 103, no. 23, pp. 2788-2791, 2001.

[17] D. Talwar, T. Quasim, D. C. McMillan, J. Kinsella, C. Williamson, and D. S. J. O'Reilly, "Pyridoxal phosphate decreases in plasma but not erythrocytes during systemic inflammatory response," Clinical Chemistry, vol. 49, no. 3, pp. 515-518, 2003.

[18] E.-P. Chiang, D. E. Smith, J. Selhub, G. Dallal, Y.-C. Wang, and R. Roubenoff, "Inflammation causes tissue-specific depletion of vitamin B6.," Arthritis research & therapy, vol. 7, no. 6, pp. R1254-1262, 2005.

[19] S.-C. Huang, J. C.-C. Wei, D. J. Wu, and Y.-C. Huang, "Vitamin B6 supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis," European Journal of Clinical Nutrition, vol. 64, no. 9, pp. 1007-1013, 2010.

[20] A. Ulvik, 0. Midttun, E. R. Pedersen, S. J. P. M. Eussen, O. Nygard, and P. M. Ueland, "Evidence for increased catabolism of vitamin B-6 during systemic inflammation," American Journal of Clinical Nutrition, vol. 100, no. 1, pp. 250-255, 2014.

[21] M. Jankowska, M. Marszall, A. Debska-Slizien et al., "Vitamin B6 and the immunity in kidney transplant recipients," Journal of Renal Nutrition, vol. 23, no. 1, pp. 57-64, 2013.

[22] M. Jankowska, P. Trzonkowski, A. Debska-Slizien et al., "Vitamin B6 status, immune response and inflammation markers in kidney transplant recipients treated with polyclonal antithymocyte globulin," Transplantation Proceedings, vol. 46, no. 8, pp. 2631-2635, 2014.

[23] A. M. Gori, A. M. Corsi, S. Fedi et al., "A proinflammatory state is associated with hyperhomocysteinemia in the elderly," American Journal of Clinical Nutrition, vol. 82, no. 2, pp. 335341, 2005.

[24] J. T. Wu, "Circulating homocysteine is an inflammation marker and a risk factor of life-threatening inflammatory diseases," Journal of Biomedical and Laboratory Sciences, vol. 19, pp. 107111, 2007.

[25] M. E. L. Oudi, Z. Aouni, C. Mazigh et al., "Homocysteine and markers of inflammation in acute coronary syndrome," Experimental and Clinical Cardiology, vol. 15, pp. e25-e28,2010.

[26] T. N. van den Kommer, M. G. Dik, H. C. Comiis, C. Jonker, and D. J. H. Deeg, "Homocysteine and inflammation: predictors of cognitive decline in older persons?" Neurobiology of Aging, vol. 31, no. 10, pp. 1700-1709, 2010.

[27] M. A. Mansoor, I. Seljeflot, H. Arnesen et al., "Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia," Clinical Biochemistry, vol. 37, no. 5, pp. 408-414, 2004.

[28] M. Li, J. Chen, Y.-S. Li, Y.-B. Feng, X. Gu, and C.-Z. Shi, "Folic acid reduces adhesion molecules VCAM-1 expession in aortic of rats with hyperhomocysteinemia," International Journal of Cardiology, vol. 106, no. 2, pp. 285-288, 2006.

[29] D. Talwar, T. Quasim, D. C. McMillan, J. Kinsella, C. Williamson, and D. S. J. O'Reilly, "Optimisation and validation of a sensitive high-performance liquid chromatography assay for routine measurement of pyridoxal 5-phosphate in human plasma and red cells using pre-column semicarbazide derivatisation," Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 792, no. 2, pp. 333-343, 2003.

[30] A. Araki and Y. Sako, "Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection," Journal of Chromatography B, vol. 422, pp. 43-52,1987.

[31] Food and Nutrition Board, Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline, National Academies Press, Washington, DC, USA, 1998.

[32] J. Selhub, P. F. Jacques, D. Rush, I. H. Rosenberg, and P. W. F. Wilson, "Vitamin Status and intake as primary determinants of homocysteinemia in an elderly population," JAMA: The Journal of the American Medical Association, vol. 270, no. 22, pp. 26932698, 1993.

[33] A. N. Friedman, L. G. Hunsicker, J. Selhub, and A. G. Bostom, "Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy," Atherosclerosis, vol. 172, no. 1, pp. 121125, 2004.

[34] L. Paul, P. M. Ueland, and J. Selhub, "Mechanistic perspective on the relationship between pyridoxal 5'-phosphate and inflammation," Nutrition Reviews, vol. 71, no. 4, pp. 239-244, 2013.

[35] P. Zhang, K. Tsuchiya, T. Kinoshita et al., "Vitamin B6 prevents IL-1[beta] protein production by inhibiting nlrp3 inflammasome activation," Journal of Biological Chemistry, vol. 291, no. 47, pp. 24517-24527, 2016.

[36] 0. Midttun, A. Ulvik, E. R. Pedersen et al., "Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation," Journal of Nutrition, vol. 141, no. 4, pp. 611-617, 2011.

[37] M. Rao, D. Guo, M. C. Perianayagam et al., "Plasma interleukin6 predicts cardiovascular mortality in hemodialysis patients," American Journal of Kidney Diseases, vol. 45, no. 2, pp. 324-333, 2005.

[38] M.-C. Chao, S.-L. Hu, H.-S. Hsu et al., "Serum homocysteine level is positively associated with chronic kidney disease in a Taiwan Chinese population," Journal of Nephrology, vol. 27, no. 3, pp. 299-305, 2014.

[39] A. N. Friedman, A. G. Bostom, J. Selhub, A. S. Levey, and I. H. Rosenberg, "The kidney and homocysteine metabolism," Journal of the American Society of Nephrology, vol. 12, no. 10, pp. 2181-2189, 2001.

[40] M. E. Suliman, B. Lindholm, P. Barany, and J. Bergstrom, "Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease," Clinical Chemistry and Laboratory Medicine, vol. 39, no. 8, pp. 734-738, 2001.

[41] H. F. Tbahriti, "Inflammatory status in chronic renal failure: the role of homocysteinemia and pro-inflammatory cytokines," World Journal of Nephrology, vol. 2, no. 2, p. 31, 2013.

[42] P. J. Kelly, J. P. Kistler, V. E. Shih et al., "Inflammation, homocysteine, and vitamin B6 status after ischemic stroke," Stroke, vol. 35, no. 1, pp. 12-15, 2004.

[43] G. Cianciolo, G. La Manna, L. Coll et al., "5-Methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients," American Journal of Nephrology, vol. 28, no. 6, pp. 941-948, 2008.

[44] G. Cianciolo, A. De Pascalis, L. Di Lullo, C. Ronco, C. Zannini, and G. La Manna, "Folic acid and homocysteine in chronic kidney disease and cardiovascular disease progression: which comes first?" Cardiorenal Medicine, pp. 255-266.

[45] A. C. T. M. Peeters, B. E. Van Aken, H. J. Blom, P. H. Reitsma, and M. Den Heijer, "The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers," Clinical Chemistry and Laboratory Medicine, vol. 45, no. 1, pp. 54-58, 2007.

[46] M. Picotte, C. G. Campbell, and W. G. Thorland, "Day-today variation in plasma interleukin-6 concentrations in older adults," Cytokine, vol. 47, no. 3, pp. 162-165, 2009.

Cheng-Hsu Chen, (1,2,3) En-Ling Yeh, (4) Chih-Chung Chen, (5) Shih-Chien Huang, (6,7) and Yi-Chia Huang (6,7)

(1) Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan

(2) Division of Basic Medical Sciences, Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan

(3) Department of Life Science, Tunghai University, Taichung 40705, Taiwan

(4) Graduate Program in Nutrition, Chung Shan Medical University, Taichung 40201, Taiwan

(5) Division of Nephrology, Department of Internal Medicine, Chiayi Branch, Taichung Veterans General Hospital, Chiayi 60090, Taiwan

(6) Department of Nutrition, Chung Shan Medical University, Taichung 40201, Taiwan

(7) Department of Nutrition, Chung Shan Medical University Hospital, Taichung 40201, Taiwan

Correspondence should be addressed to Yi-Chia Huang;

Received 6 June 2017; Revised 11 August 2017; Accepted 20 August 2017; Published 26 September 2017

Academic Editor: Charnita M. Zeigler-Johnson
Table 1: Demographic and clinical characteristics of patients
with chronic kidney disease or those receiving hemodialysis.

Characteristics                     Stage 2-3 CKD (n = 34)

Age (y)                            52.76 [+ or -] 16.11 (a)
Gender (Male/Female)                        21/13
Waist circumference (cm)           87.96 [+ or -] 1.53 (a)
Body mass index (kg/[m.sup.2])       23.74 [+ or -] 3.63
Blood pressure (mmHg)
Systolic                           127.44 [+ or -] 2.26 (a)
Diastolic                            74.59 [+ or -] 1.41
Antihypertensive                          22, 64.71%
medication uses (n, %)
eGFR (mL/min/1.73 [m.sup.2])       55.65 (a) [+ or -] 2.83
Serum creatinine (mg/dL)            1.38 [+ or -] 0.06 (a)
BUN (mg/dL)                        21.39 [+ or -] 1.10 (a)
Serum albumin (g/dL)                4.40 [+ or -] 0.04 (a)
<3.5 g/dL (n, %)                              0
Serum glucose (mg/dL)                97.24 [+ or -] 4.91
Diabetes (n, %)                           5 (14.71%)
Antidiabetic                              7, 20.59%
medication uses (n, %)

Total cholesterol (mg/dL)          187.12 [+ or -] 5.76 (a)
Lipid lowering                            13, 38.24%
medication uses (n, %)

B-vitamin supplement
uses (n, %)
Yes                                           0
No                                         34,100%
Current smoking habit (n, %)
Yes                                        6,17.65%
No                                        27, 79.41%
Current drinking habit (n, %)
Yes                                        5,14.71%
No                                        29, 85.29%

Characteristics                     Stage 4-5 CKD (n = 34)

Age (y)                            57.53 [+ or -] 12.10 (b)
Gender (Male/Female)                        24/10
Waist circumference (cm)           88.67 [+ or -] 1.81 (a)
Body mass index (kg/[m.sup.2])       25.17 [+ or -] 3.43
Blood pressure (mmHg)
Systolic                           134.59 [+ or -] 2.27 (a)
Diastolic                            76.41 [+ or -] 2.05
Antihypertensive                          30,11.81%
medication uses (n, %)
eGFR (mL/min/1.73 [m.sup.2])       17.77 [+ or -] 1.06 (b)
Serum creatinine (mg/dL)            3.84 [+ or -] 0.25 (b)
BUN (mg/dL)                        51.79 [+ or -] 2.81 (b)
Serum albumin (g/dL)                4.15 [+ or -] 0.06 (a)
<3.5 g/dL (n, %)                           1, 0.03%
Serum glucose (mg/dL)                114.06 [+ or -] 6.75
Diabetes (n, %)                          13 (38.24%)
Antidiabetic                              14, 41.18%
medication uses (n, %)

Total cholesterol (mg/dL)        169.41 [+ or -] 8.23 (a)- (b)
Lipid lowering                            19, 55.88%
medication uses (n, %)

B-vitamin supplement
uses (n, %)
Yes                                       6 (17.65%)
No                                        28, 82.35%
Current smoking habit (n, %)
Yes                                        4,11.76%
No                                        30, 88.24%
Current drinking habit (n, %)
Yes                                        2, 5.88%
No                                        32, 94.12%

Characteristics                     Hemodialysis (n = 68)

Age (y)                            61.56 [+ or -] 10.61 (c)
Gender (Male/Female)                        34/34
Waist circumference (cm)           82.93 [+ or -] 1.50 (b)
Body mass index (kg/[m.sup.2])       23.70 [+ or -] 3.91
Blood pressure (mmHg)
Systolic                           149.85 [+ or -] 3.23 (b)
Diastolic                            74.15 [+ or -] 1.97
Antihypertensive                          43, 63.23%
medication uses (n, %)
eGFR (mL/min/1.73 [m.sup.2])        4.67 [+ or -] 0.17 (c)
Serum creatinine (mg/dL)           11.13 [+ or -] 0.28 (c)
BUN (mg/dL)                        64.09 [+ or -] 1.90 (c)
Serum albumin (g/dL)                3.82 [+ or -] 0.04 (b)
<3.5 g/dL (n, %)                           9,13.24%
Serum glucose (mg/dL)                108.16 [+ or -] 4.71
Diabetes (n, %)                          29 (42.65%)
Antidiabetic                              28, 41.18%
medication uses (n, %)

Total cholesterol (mg/dL)          160.71 [+ or -] 3.96 (b)
Lipid lowering                             9,13.24%
medication uses (n, %)

B-vitamin supplement
uses (n, %)
Yes                                      33 (48.53%)
No                                        35, 51.47%
Current smoking habit (n, %)
Yes                                        1,1.47%
No                                        67, 98.53%
Current drinking habit (n, %)
Yes                                           0
No                                         68,100%

Values are means [+ or -] standard error. eGFR, estimated glomerular
filtration rate; BUN, blood urea nitrogen; a,b,c Values with a
different superscript letter are significantly different among
groups; p < 0.05.

Table 2: Vitamin B-6 status and inflammatory markers in patients
with chronic kidney disease or those receiving hemodialysis.

                                           Stage 2-3 CKD
                                              (n = 34)

Vitamin B-6 status
Pyridoxal 5'-phosphate (nmol/L)       58.50 [+ or -] 8.52 (a)
<20 nmol/L (n, %)                             3, 8.82%
Pyridoxal (nmol/L)                      15.85 [+ or -] 1.71
Homocysteine ([micro]mol/L)           15.32 [+ or -] 0.65 (a)
[greater than or equal                       22, 64.71%
to] 14 [micro]mol/L (n, %)
Inflammatory markers
C-reactive protein (mg/L)              1.49 [+ or -] 0.52 (a)
Interleukin-1[beta] (pg/mL)           1.28 [+ or -] 0.58 (a,b)
Interleukin-4 (pg/mL)                    1.21 [+ or -] 0.30
Interleukin-6 (pg/mL)                   10.38 [+ or -] 2.18
Interleukin-8 (pg/mL)                    8.86 [+ or -] 1.31
Interleukin-10 (pg/mL)                13.76 [+ or -] 2.78 (a)
TNF-[alpha] (pg/mL)                   26.36 [+ or -] 8.35 (a)

                                           Stage 4-5 CKD
                                              (n = 34)

Vitamin B-6 status
Pyridoxal 5'-phosphate (nmol/L)      84.31 [+ or -] 21.64 (a,b)
<20 nmol/L (n, %)                            5, 14.71%
Pyridoxal (nmol/L)                      22.03 [+ or -] 4.82
Homocysteine ([micro]mol/L)             28.22 [+ or -] 1.57b
[greater than or equal                        34, 100%
to] 14 [micro]mol/L (n, %)
Inflammatory markers
C-reactive protein (mg/L)               3.86 [+ or -] 1.00b
Interleukin-1[beta] (pg/mL)           1.48 [+ or -] 0.18 (a,c)
Interleukin-4 (pg/mL)                    0.97 [+ or -] 0.10
Interleukin-6 (pg/mL)                    6.80 [+ or -] 0.97
Interleukin-8 (pg/mL)                    7.73 [+ or -] 0.65
Interleukin-10 (pg/mL)                  3.92 [+ or -] 0.61b
TNF-[alpha] (pg/mL)                     26.58 [+ or -] 5.42b

                                              (n = 68)

Vitamin B-6 status
Pyridoxal 5'-phosphate (nmol/L)      148.16 [+ or -] 26.76 (b)
<20 nmol/L (n, %)                             2, 2.94%
Pyridoxal (nmol/L)                      30.08 [+ or -] 4.37
Homocysteine ([micro]mol/L)           27.08 [+ or -] 1.03 (b)
[greater than or equal                        68, 100%
to] 14 [micro]mol/L (n, %)
Inflammatory markers
C-reactive protein (mg/L)              4.82 [+ or -] 1.17 (b)
Interleukin-1[beta] (pg/mL)            1.18 [+ or -] 0.31 (b)
Interleukin-4 (pg/mL)                    1.12 [+ or -] 0.17
Interleukin-6 (pg/mL)                    6.36 [+ or -] 1.27
Interleukin-8 (pg/mL)                   10.11 [+ or -] 1.59
Interleukin-10 (pg/mL)                 6.35 [+ or -] 1.57 (b)
TNF-[alpha] (pg/mL)                  32.11 [+ or -] 13.50 (a,b)

Values are means [+ or -] standard error. TNF-[alpha], tumor
necrosis factor-[alpha]; a' 'cValues with a different superscript
letter are significantly different among groups; p < 0.05.

Table 3: Partial Spearman's correlation coefficients (rs) of vitamin
B-6 and homocysteine with inflammatory markers in all patients.

                                            [r.sub.s] (no additionally
Parameters                                  adjusted homocysteine)

                                  PLP           PL       PLP + PL
                                (nmol/L)     (nmol/L)    (nmol/L)

CRP (mg/L)                      -0.22 *         --        -0.21 *
Interleukin-1[beta] (pg/mL)        i            --        0.22 *
Interleukin-4 (pg/mL)              --           --          --
Interleukin-6 (pg/mL)              --           --          --
Interleukin-8 (pg/mL)              --           --          --
Interleukin-10 (pg/mL)             --        -0.21 *        --
TNF-[alpha] (pg/mL)                --           --          --

                                            [r.sub.s] (additionally
Parameters                                  adjusted homocysteine)

                                  PLP          PL       PLP + PL
                                (nmol/L)    (nmol/L)    (nmol/L)

CRP (mg/L)                      -0.22 *        --        -0.22 *
Interleukin-1[beta] (pg/mL)        --          --        0.22 *
Interleukin-4 (pg/mL)              --          --          --
Interleukin-6 (pg/mL)              --          --          --
Interleukin-8 (pg/mL)              --          --          --
Interleukin-10 (pg/mL)             --        -0.23 *       --
TNF-[alpha] (pg/mL)                --          --          --

N = 136. Values are partial correlation coefficient (rs). * p <
0.05. Adjusting for age, gender, body mass index, systolic blood
pressure, serum albumin, diabetes, chronic kidney disease stage,
plasma homocysteine, B-vitamin supplement usage, smoking and
drinking habits; PLP, pyridoxal 5'-phosphate; PL, pyridoxal; CRP, C-
reactive protein; TNF-[alpha], tumor necrosis factor-[alpha];
'No significance.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Chen, Cheng-Hsu; Yeh, En-Ling; Chen, Chih-Chung; Huang, Shih-Chien; Huang, Yi-Chia
Publication:BioMed Research International
Article Type:Report
Date:Jan 1, 2017
Previous Article:The Interaction between GSTT1, GSTM1, and GSTP1 Ile15Val Gene Polymorphisms and Environmental Risk Factors in premalignant gastric Lesions Risk.
Next Article:Inhibitory Effect of Chemical Constituents Isolated from Artemisia iwayomogi on Polyol Pathway and Simultaneous Quantification of Major Bioactive...

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters